Dysregulation of autocrine TGF-β isoform production and ligand responses in human tumour-derived and Ha-ras-transfected keratinocytes and fibroblasts

British Journal of Cancer

Volumn 74, Issue 7, 1996, Pages 1074-1080

  Fahey, M S ^a   Paterson, I C ^a   Stone, A ^a   Collier, A J ^a   Heung, Y L M ^a   Davies, M ^a   Patel, V ^a   Parkinson, E K ^b   Prime, S S ^a,c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^c BRISTOL DENTAL HOSPITAL   (United Kingdom)

Author keywords

Fibroblast; Ha ras; Isoform; Keratinocyte; Transforming growth factor beta

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KERATINOCYTE; MOUTH MUCOSA; ONCOGENE H RAS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0029784956     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.492     Document Type: Article

References (45)

1. ARTEAGA CL, COFFEY RJ, DUGGER TC, MCCUTCHEN CM, MOSES HL AND LYONS RM. (1990). Growth stimulation of human breast cancer cells with anti-transforming growth factor β antibodies: evidence for negative autorine regulation by transforming growth factor. Cell Growth Different., 1, 367-374.
2. ARTEAGA CL, DUGGER TC, WINNIER AR AND FORBES JT. (1993). Evidence for a positive role of transforming growth factor-β in human breast cancer cell tumorigenesis. J. Cell. Biochem., 17G, 187-193.
3. BOUKAMP P., STANBRIDGE EJ, YIN FOO D, CERUTTI PA AND FUSENIG NE. (1990). c-Ha-ras oncogene expression in immortalised human keratinocytes (HaCaT) alters growth potential in vivo but lacks correlation with malignancy. Cancer Res., 50, 2840-2847.
4. BURNS JE, BAIRD MC, CLARK LJ, BURNS PA, EDINGTON K, CHAPMAN C, MITCHELL R, ROBERTSON G, SOUTAR D AND PARKINSON EK. (1993). Gene mutations and increased levels of p53 protein in human squamous cell carcinomas and their cell lines. Br. J. Cancer, 67, 1274-1284.
5. CHEIFETZ S, HERNANDEZ J, LAIHO M, TEN DIFKE P, IWATA KK AND MASSAGUE J. (1990). Distinct transforming growth factor-β (TGF-β receptor subsets as determinants of cellular responsiveness to three TGF-β isoforms. J. Biol. Chem., 265, 20533-20538.
6. CLARK LJ, EDINGTON K, SWAN IRC, MCLAY KA, NEWLANDS WJ, WILLS LC, YOUNG HA, JOHNSTONE PW, MITCHELL R, ROBERTSON G, SOUTAR D, PARKINSON EK AND BIRNIE GD. (1993). The absence of Harvey ras mutations during development and progression of squamous cell carcinomas of the head and neck. Br. J. Cancer, 68, 617-620.
7. COFFEY RJ, BASCOM CC, SIPES NJ, GRAVES-DEAL R, WEISSMAN BE AND MOSES HL. (1988). Selected inhibition of growth related gene expression in murine keratinocytes by transforming growth factor β. Mol. Cell Biol., 8, 3088-3093.
8. COLLETTA AA, WAKEFIELD LM, HOWELL FV, VAN R, DANIELPOUR D, EBBS SR, SPORN MB AND BAUM M. (1990). Antioestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br. J. Cancer, 62, 405-409.
9. COOMBS LM, PIGOTT DA, EYDMANN ME, PROCTOR AJ AND KNOWLES MA. (1993). Reduced expression of TGF-β is associated with advanced disease in transitional cell carcinoma. Br. J. Cancer, 67, 578-584.
10. nul1 mice is prognostic for a high risk of malignant conversion. Cancer Res., 54, 5831-5836.
11. DANIELPOUR D. (1993). Improved sandwich enzyme-linked immunosorbent assays for transforming growth factor β1. J. Immunol. Methods, 158, 17-25.
12. DANIELPOUR D, KIM KY, WINOKUR TS AND SPORN MB. (1991). Differential regulation of the regulation of transforming growth factor-βs 1 and 2 by retinoic acid, epidermal growth factor and dexamethasone in NRK-49F and A549 cells. J. Cell. Physiol., 148, 235-244.
13. DERYNCK R, GOEDDEL DV, ULLRICH A, GUTTERMAN JY, WILLIAMS RD AND BRINGMAN TS. (1987). Synthesis of messenger RNAs for transforming growth factor α and β and the epidermal growth factor receptor by human tumours. Cancer Res., 47, 707-712.
14. DOTTO GP, WEINBERG RA AND ARIZA A. (1988). Malignant transformation of mouse primary keratinocytes by Harvey sarcoma virus and its modulation by surrounding normal cells. Proc. Natl Acad. Sci. USA, 85, 6389-6393.
15. EDINGTON KG, LOUGHRAM OP, BERRY IJ AND PARKINSON EK. (1995). Cellular immortality-a late event in the progression of human squamous cell carcinoma of the head and neck associated with p53 alteration and a high frequency of allele loss. Mol. Carcinogen., 13, 254-265.
16. FYNAN TM AND REISS M. (1993). Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis. Crit. Rev. Oncogen., 4, 493-540.
17. GAME SM, HUELSON A, PATEL V, DONNELLY M, YEUDALL WA, STONE A, FUSENIG NE AND PRIME SS. (1992). Progressive abrogation of TGF-β1 and EGF growth control is associated with tumour progression in ras-transfected human keratinocytes. Int. J. Cancer, 52, 461-470.
18. GEISER AG, KIM SJ, ROBERTS AB AND SPORN MB. (1991). Characterisation of the mouse transforming growth factor-β1 promoter and activation by the Ha-ras oncogene. Mol. Cell. Biol., 11, 84-92.
19. GLICK AB, KULKARNI AB, TENNENBAUM T, HENNINGS J, FLANDERS KC, O'REILLY M, SPORN MB, KARLSSON S AND YUSPA SH. (1993). Loss of expression of transforming growth factor β in skin and skin tumours is associated with hyperproliferation and a high risk for malignant conversion. Proc. Natl Acad. Sci. USA. 90, 6076-6080.
20. GLICK AB, LEE MM, DARWICHE N, KULKARNI AB, KARLSSON S AND YUSPA SH. (1994). Targeted deletion of the TGF-β1 gene causes rapid progression to squamous cell carcinoma. Genes Dev., 8, 2429-2440.
21. GORSCH SM, MEMOLI VA, STUKEL TA, GOLD LI AND ARRICK BA. (1992). Immunohistochemical staining for transforming growth factor-β1 associates with disease progression in human breast cancer. Cancer Res., 52, 6949-6952.
22. HAFEZ MM, INFANTE D, WINAWER S AND FRIEDMAN E. (1990). Transforming growth factor beta 1 acts as an autocrine-negative growth regulator in colon enterocytic differentiation but not in goblet cell maturation. Cell Growth Different., 1, 617-626.
23. JENNINGS JC, MOHAN S, LINKHART TA, WIDSTROM R AND BAYLINK DJ. (1988). Differential activity in endothelial cells. J. Cell Physiol., 137, 167-172.
24. KIM SJ, PARK K, KOELLER D, KIM KY, WAKEFIELD LM, SPORN MB AND ROBERTS AB. (1992). Post-transcriptional regulation of the human transforming growth factor-beta 1 gene. J. Biol. Chem., 267, 13702-13707.
25. LAWRENCE DA. (1995). Transforming growth factor-β: an overview. Kidney Int., 47, S19-S23.
26. LEHMAN TA, MODALI R, BOUKAMP P, STANEK J, BENNETT WP, WELSH JA, METCALF RA, STAMPFER MR, FUSENIG NE, ROGAN EM, REDDEL R AND HARRISCC. (1993). p53 mutations in human immortalised epithelial cell lines. Carcinogenesis, 14, 833-839.
27. LEVINE JH, MOSES HL, GOLD LI AND NANNEY LB. (1993). Spatial and temporal patterns of immunoreactive TGF-β1, TGF-β2 and TGF-β3 during excisional wound repair. Am. J. Pathol., 143, 368-380.
28. MACCALLUM J, BARTLETT JMS, THOMPSON AM, KEEN JC, DIXON JM AND MILLER WR. (1994). Expression of transforming growth factor-β mRNA isoforms in human breast cancer. Br. J. Cancer, 69, 1006-1009.
29. MISSERO C, CAJAL SR AND DOTTO GP. (1991). Escape from transforming growth factor β control and oncogene cooperation in skin tumor development. Proc. Natl Acad. Sci. USA, 88, 9613-9617.
30. MUNGER K, PIETENPOL JA, PITTELKOW MR, HOLT JT AND MOSES HL. (1992). Transforming growth factor β1 regulation of c-myc expression, pRB phosphorylation and cell cycle progression in keratinocytes. Cell Growth Different., 3, 291-298.
31. PATAMALAI B, BUROW DL, GIMENEZ-CONTI I, ZENKLUSEN JC, CONTI CJ, KLEIN-SZANTO AJP AND FISCHER SM. (1994). Altered expression of transforming growth factor-β1 mRNA and protein in mouse skin carcinogenesis. Mol. Carcinogen., 9, 220-229.
32. PELTON RW, SAXENA B, JONES M, MOSES HL AND GOLD LI. (1991). Immunohistochemical localization of TGF-β1, TGF-β2 and TGF-β3 in the mouse embryo: expression patterns suggest multiple roles during embryonic development. J. Cell Biol., 115, 1091-1105.
33. PIETENPOL JA, HOLT JT, STEIN RW AND MOSES HL. (1990). Transforming growth factor-β suppression of c-myc gene transcription: role in inhibition of keratinocyte proliferation. Proc. Natl Acad. Sci. USA, 87, 3758-3762.
34. PRIME SS, NIXON SVR, CRANE IJ, STONE A, MATTHEWS JB, MAITLAND NJ, REMNANT L, POWELL SK, GAME SM AND SCULLY C. (1990). The behaviour of human oral squamous cell carcinoma in cell culture. J. Pathol., 160, 259-269.
35. PRIME SS, MATTHEWS JB, PATEL V, GAME SM, DONNELLY M, STONE A, PATERSON IC, SANDY JR AND YEUDALL WA. (1994). TGF-β receptor regulation mediates the response to exogenous ligand but is independent of the degree of cellular differentiation in human oral keratinocytes. Int. J. Cancer, 56, 406-412.
36. ROBERTS AB AND SPORN MB. (1991). The transforming growth factors. In Peptide Growth Factors and their Receptors I. Sporn MB and Roberts AB (eds) pp. 419-472. Springer: Berlin.
37. SCHOR AM, RUSHTON G, FERGUSON JE, HOWELL A. REDFORD J AND SCHOR SL. (1994). Phenotypic heterogeneity in breast fibroblasts: functional anomaly in fibroblasts from histologically normal tissue adjacent to carcinoma. Int. J. Cancer, 59, 25-32.
38. SHAH M, FOREMAN DM AND FERGUSON MWJ. (1995). Neutralization of TGF-β1 and TGF-β2 or exogenous addition of the TGF-β3 to cutaneous rat wounds reduces scarring. J. Cell Sci., 108, 985-1002.
39. SPORN MB AND ROBERTS AB. (1992). Transforming growth factor-B: recent progress and new challenges. J. Cell. Biol., 119, 1017-1021.
40. TAKIUCHI H, TADA T, LI X-F, OGATA M, IKEDA T, EUJIMOTO S, FUJIWARA H AND HAMAOKA T. (1992). Particular types of tumour cells have the capacity to convert transforming growth factor β from a latent to an active form. Cancer Res., 52, 5641-5646.
41. TEN DIJKEP, IWATA KK, THORIKAY M, SCHWEDES J, STEWART A AND PIELER C. (1990). Molecular characterisation of transforming growth factor type β3. Ann. NY Acad. Sci., 593, 26-42.
42. WELCH DR, FABRA A AND NAKAJIMA M. (1990). Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc. Natl Acad. Sci. USA, 87, 7678-7682.
43. WU S, THEODORESCU D, KERBEL RS, WILLSON JKV, MULDER KV, HUMPHREY LE AND BRATTAIN MG. (1992). TGF-β1 is an autocrine-negativc growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an anti-sense expression vector. J. Cell Biol., 116, 187-196.
44. YEUDALL WA, TORRANCE LK, ELSEGOOD KA, SPEIGHT PA AND PRIME SS. (1993). Ras gene point mutation is a rare event in premalignant and malignant lesions of the oral cavity. Eur, J. Cancer, 29B, 63-68.
45. YEUDALL WA, PATERSON IC, PATEL V AND PRIME SS. (1995). Presence of human papillomavirus sequences in tumour-derived human oral keratinocytes which express mutant p53. Eur. J. Cancer, 31B, 136-143.